PARTNERSHIPs
Evozyne partnered with leaders in AI, pharmaceutical development and global health on several proof-of-concept projects that demonstrate the power of our platform.
NVIDIA
Evozyne collaborated with NVIDIA to create and validate the BioNeMo model, a foundational tool for AI-guided drug discovery.
The novel approach exponentially increased the number and quality of synthetic protein designs for experimental testing. That capability translates to the ability to design new therapeutic targets for currently untreated diseases and greatly reduces development time for new
therapies.
- Evozyne’s Protein Transformer Variational AutoEncoder (ProT-VAE) is built on NVIDIA BioNeMo
- Repeatable, functional results in less than 12 months
- Produced two novel proteins validated in experimental tests
- A biologic with 2.5-times better catalytic activity than wild type
- An enzyme with 61°C higher thermostability than the natural protein
Takeda
Takeda and Evozyne partnered to address treatment challenges in rare diseases and to develop transformative options for patients.
- Delivered first result in 6 months.
- Designed a library of novel proteins with greatly improved functionality.
- Developed functional miniaturized genes that may aid in overcoming size constraints of viral vectors.
Gates Foundation
The Gates Foundation and Evozyne collaborated to increase the thermal stability of a key driver of human health.
- Increased thermal stability of large protein complex by 5°C while maintaining the activity of interest.
- Developed multiple libraries with a ~95% rate of activity and enhanced temperature resilience.
- Built models and assays that can be used to engineer a wide range of plant species.